Data / Drug companies / Slate Run Pharmaceuticals, LLC
Slate Run Pharmaceuticals, LLC: 121 products in the FDA NDC directory, labeler code 70436
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Slate Run Pharmaceuticals, LLC (labeler code 70436) lists 121 products in the FDA National Drug Code Directory, covering 44 finished drugs by generic name. By type: 121 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 31, 2026.
The request: Watch Slate Run Pharmaceuticals, LLC (FDA labeler code 70436): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 70436
- Products in commercial distribution
- 121
- Packages
- 194
- Finished drugs by generic name
- 44
- Prescription products
- 121
- Over the counter products
- 0
- Flagged as original packager
- 113 of 113 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- August 2, 2017
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 121 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 121 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Diltiazem hydrochloride | 9 | 55 |
| Gadobutrol | 8 | 6 |
| Iopamidol | 6 | 2 |
| Leucovorin calcium | 5 | 18 |
| Azithromycin dihydrate | 5 | 20 |
| Bupropion hydrochloride | 5 | 67 |
| Vancomycin hydrochloride | 4 | 39 |
| Eptifibatide | 4 | 9 |
| Potassium chloride | 4 | 84 |
| Guanfacine | 4 | 33 |
| Memantine hydrochloride | 4 | 36 |
| Metoprolol succinate | 4 | 46 |
| Galantamine | 3 | 8 |
| Droxidopa | 3 | 15 |
| Sodium nitroprusside in 0.9% sodium chloride | 3 | 1 |
| Desvenlafaxine | 3 | 14 |
| Cisatracurium besylate | 3 | 15 |
| Cyclophosphamide for injection | 3 | 3 |
| Lincomycin | 2 | 3 |
| Cilostazol | 2 | 10 |
| Mycophenolic acid | 2 | 16 |
| Levoleucovorin injection | 2 | 2 |
| Voriconazole | 2 | 34 |
| Tolterodine tartrate | 2 | 13 |
| Gadoterate meglumine | 2 | 4 |
| Doxycycline hyclate | 2 | 61 |
| Ganciclovir sodium | 2 | 5 |
| Tetrabenazine | 2 | 12 |
| Amiodarone hydrochloride | 1 | 35 |
| Sodium nitroprusside | 1 | 14 |
| Acyclovir | 1 | 70 |
| Mometasone furoate monohydrate | 1 | 8 |
| Trospium chloride | 1 | 22 |
| Dicyclomine hydrochloride | 1 | 50 |
| Daptomycin | 1 | 25 |
| Tobramycin | 1 | 41 |
| Methocarbamol | 1 | 67 |
| Fluconazole | 1 | 48 |
| Bivalirudin | 1 | 13 |
| Gadoteridol | 1 | 2 |
| Oseltamivir phosphate | 1 | 37 |
| Arformoterol tartrate inhalation | 1 | 2 |
| Esomeprazole sodium | 1 | 3 |
| Dobutamine | 1 | 4 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 24 | 19.8% |
| Tablet, extended release | 22 | 18.2% |
| Injection, powder, lyophilized, for solution | 14 | 11.6% |
| Injection, solution | 12 | 9.9% |
| Capsule, extended release | 10 | 8.3% |
| Tablet, film coated | 8 | 6.6% |
| Powder, for suspension | 6 | 5% |
| Tablet, film coated, extended release | 4 | 3.3% |
| Tablet | 4 | 3.3% |
| Capsule | 4 | 3.3% |
| Injection, powder, for solution | 4 | 3.3% |
| Tablet, delayed release | 2 | 1.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Mometasone Furoate Monohydrate | 70436-154 | Spray, metered | Generic drugs (ANDA) | October 31, 2026 |
| Olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide | 70436-018 | Tablet, film coated | Generic drugs (ANDA) | May 15, 2025 |
| Olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide | 70436-017 | Tablet, film coated | Generic drugs (ANDA) | May 15, 2025 |
| Olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide | 70436-016 | Tablet, film coated | Generic drugs (ANDA) | May 15, 2025 |
| Olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide | 70436-015 | Tablet, film coated | Generic drugs (ANDA) | May 15, 2025 |
| Olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide | 70436-014 | Tablet, film coated | Generic drugs (ANDA) | May 15, 2025 |
| Gadobutrol | 70436-218 | Injection | Generic drugs (ANDA) | April 16, 2025 |
| Gadobutrol | 70436-217 | Injection | Generic drugs (ANDA) | April 16, 2025 |
| Gadobutrol | 70436-217 | Injection | Generic drugs (ANDA) | April 16, 2025 |
| Gadobutrol | 70436-216 | Injection | Generic drugs (ANDA) | April 16, 2025 |
| Gadobutrol | 70436-216 | Injection | Generic drugs (ANDA) | April 16, 2025 |
| Gadobutrol | 70436-213 | Injection | Generic drugs (ANDA) | April 16, 2025 |
| Cyclophosphamide | 70436-107 | Injection, powder, for solution | Generic drugs (ANDA) | March 26, 2025 |
| Cyclophosphamide | 70436-106 | Injection, powder, for solution | Generic drugs (ANDA) | March 26, 2025 |
| Cyclophosphamide | 70436-105 | Injection, powder, for solution | Generic drugs (ANDA) | March 26, 2025 |
| Gadoteridol | 70436-121 | Injection | Generic drugs (ANDA) | February 20, 2025 |
| Leucovorin Calcium | 70436-119 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | December 27, 2024 |
| Amiodarone Hydrochloride | 70436-232 | Injection, solution | Generic drugs (ANDA) | October 31, 2024 |
| Doxycycline hyclate | 70436-201 | Powder, for solution | Generic drugs (ANDA) | July 22, 2024 |
| Doxycycline hyclate | 70436-032 | Powder, for solution | Generic drugs (ANDA) | July 22, 2024 |
| Methocarbamol | 70436-149 | Injection | Generic drugs (ANDA) | July 1, 2024 |
| Gadoterate meglumine | 70436-123 | Injection | Generic drugs (ANDA) | June 28, 2024 |
| Gadoterate meglumine | 70436-123 | Injection | Generic drugs (ANDA) | June 28, 2024 |
| Iopamidol | 70436-219 | Injection, solution | Generic drugs (ANDA) | April 15, 2024 |
| Iopamidol | 70436-211 | Injection, solution | Generic drugs (ANDA) | April 15, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.